Country: UNITED KINGDOM | Region: EUROPE | Type: Regulation | Keywords: #clinical #covid19 #dhsc #national #trial #uk
- The initiative will accelerate the development of new drugs for patients hospitalised with COVID-19, reducing the time taken to set up clinical studies for new therapies from months to weeks
- Six potential drugs will initially enter the program, with the first of these beginning phase 2 studies across the UK imminently
- This will give an early indication of whether these drugs could save lives and improve the outcomes of the most vulnerable patients with COVID-19
LONDON, United Kingdom — The UK’s Department of Health and Social Care (DHSC) has announced that thousands of patients could benefit from potential treatments for COVID-19 that will be fast-tracked through a new national clinical trial.
The new platform is set to accelerate the development of new drugs for patients hospitalised with COVID-19, reducing the time taken to set up clinical studies for new therapies from months to just weeks and helping to ease pressure on the NHS and ultimately save lives.
As it stands, 6 potential drugs will initially enter the program, with the first of these beginning phase 2 studies across the UK imminently.
“Currently no drugs in the world have been clinically proven to treat COVID-19.But our Therapeutics Taskforce has identified a number of promising candidates. Currently, 6 different treatments have been entered into national clinical trials and the first is ready to enter the next stage: a new early phase clinical trial platform that we are launching today” explained Health and Social Care Secretary, Matt Hancock.
He continued, “This is a national effort made possible by government, academia and industry working together.”
The collaborative platform, dubbed ACCORD (Accelerating COVID-19 Research & Development platform), is funded by by the DHSC and the UK Research and Innovation (UKRI) in order to get an early indication of drug treatments’ effectiveness in treating coronavirus. If positive results are seen, these drugs will advance rapidly into the large-scale trials currently in progress across the country.